Open Access Green as soon as Postprint is submitted to ZB.
Treatment of cervical dystonia with abo- and onabotulinumtoxinA: Long-term safety and efficacy in daily clinical practice.
J. Neurol. 266, 1879-1886 (2019)
Introduction Treatment with botulinum toxin A is the evidence-based first-line therapy of cervical dystonia. The aim of this study was to analyze long-term data of the most commonly used products concerning safety and efficacy in a big cohort over decades.Methods We retrospectively analyzed the treatment data of all cervical dystonia patients in our outpatient clinic having at least three treatment sessions with current onabotulinumtoxinA or abobotulinumtoxinA. The observation period was up to 17 years for onabotulinumtoxinA and 27 years for abobotulinumtoxinA. We report on safety and efficacy, comparing parameters such as dose, treatment intervals, side effects, occurrence and reasons of primary or secondary non-response.Results We analyzed a total of 2592 and 6660 treatment sessions in 135 patients with onabotulinumtoxinA, 209 with abobotulinumtoxinA and 10 having received both preparations. We found a moderate increase of dosage in the first years which was succeeded by a stable mean dose (138 and 663 mouse units, respectively) and stable injection intervals from the beginning. The most frequent side effects were mild dysphagia (2/6%), muscle weakness (2/6%) and pain (2/2%). Reasons for therapy discontinuation were change to a nearby doctor, age, other diseases, spontaneous improvement, side effects or possible treatment failure. Of all patients, only two tested positive for neutralizing antibodies against botulinum toxin A.Conclusion We show that treatment of cervical dystonia with the two most frequently used botulinum toxin A preparations is a safe and effective therapy even over a long treatment duration of up to 27 years.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Cervical Dystonia ; Abobotulinumtoxina ; Onabotulinumtoxina ; Long-term Treatment ; Botulinum Toxin A; Botulinum-toxin-a; Rating-scales; Follow-up; Therapy; Immunogenicity; Satisfaction; Injections
ISSN (print) / ISBN
0340-5354
e-ISSN
1432-1459
Journal
Journal of Neurology
Quellenangaben
Volume: 266,
Issue: 8,
Pages: 1879-1886
Publisher
Springer
Publishing Place
Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Neurogenomics (ING)